Varenicline in the management of smoking cessation: a single technology appraisal.

Health technology assessment (Winchester, England)

Volumn 13 Suppl 2, Issue , 2009, Pages 9-13

  Hind, D ^a   Tappenden, P ^b   Peters, J ^b   Kenjegalieva, K ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; BENZAZEPINE DERIVATIVE; NICOTINIC AGENT; QUINOXALINE DERIVATIVE; VARENICLINE;

CLINICAL TRIAL (TOPIC); COST BENEFIT ANALYSIS; ECONOMICS; HUMAN; METHODOLOGY; QUALITY ADJUSTED LIFE YEAR; REVIEW; SMOKING CESSATION;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BENZAZEPINES; BUPROPION; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; HUMANS; NICOTINIC AGONISTS; QUALITY-ADJUSTED LIFE YEARS; QUINOXALINES; SMOKING CESSATION;

MLCS; MLOWN;

EID: 84886943141     PISSN: None     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta13suppl2/02     Document Type: Review

References (9)